Tweetovi

Blokirali ste korisnika/cu @AbCelleraBio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AbCelleraBio

  1. 23. sij

    AbCellera is mobilizing to respond to the Wuhan coronavirus outbreak as part of the DARPA P3 program.

    Poništi
  2. 13. sij

    How to select the best therapeutic candidates when you have hundreds of antibody sequences? Celium, our custom visualization software, helps partners navigate rich datasets to select their favorite leads. See how:

    Poništi
  3. 18. pro 2019.

    Check out our new website! Find out more about the expertise and technologies behind AbCellera's therapeutic antibody discovery engine.

    Poništi
  4. 7. stu 2019.

    AbCellera announces patents on the use of microfluidics for high-throughput single-cell assays that extend protection of its market-leading technology in antibody discovery and clone selection.

    Poništi
  5. 31. lis 2019.

    We’re excited to announce that Michael Hayden, a successful entrepreneur and translational scientist, has joined AbCellera’s board of directors. Welcome Dr. Hayden!

    Poništi
  6. 1. lis 2019.

    Lead Celium(TM) Developer, Maia Smith, speaks at today at 1:30pm on the Main Stage. Learn how Celium(TM) helps AbCellera’s scientists and partners choose lead therapeutic candidates from hundreds of diverse antibody sequences. Read more here:

    Poništi
  7. 27. ruj 2019.

    AbCellera has been working hard, and it shows! AbCellera ranked Canada’s fastest growing biotech and one of Vancouver’s top 10 fastest growing companies among Canada’s Top Growing Companies.

    Poništi
  8. 5. ruj 2019.

    AbCellera appoints Andrew Booth as Chief Financial Officer and Tryn Stimart as General Counsel. With their added leadership in finance, intellectual property, and strategy, AbCellera is set for rapid growth.

    Poništi
  9. 2. srp 2019.

    AbCellera was named Company of the Year - Scale Success at Technology Impact Awards! We are proud to be nominated among BC's innovators, developing tech to solve therapeutic problems. Join us!

    Poništi
  10. 13. lip 2019.

    AbCellera announced today that it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic antibody candidates for infectious diseases.

    Poništi
  11. 11. lip 2019.

    At AbCellera, we choose to work with people who are passionate, intelligent, and team players. Those guiding values just happen to have created a diverse and balanced team. Congratulations to all those whose hard work and contributions were recognized by .

    Poništi
  12. 3. lip 2019.

    AbCellera completes the fundraising ride after logging 1961.27 km in the Week!

    Poništi
  13. 9. svi 2019.

    AbCellera announces partnership with Vaccine Research Center and Systems to develop a nucleic acid encoded countermeasure against pandemic .

    Poništi
  14. 12. tra 2019.

    Learn how AbCellera is using its technology to develop a rapid response platform. Join us at the World Vaccine Congress in Washington.

    Poništi
  15. 26. ožu 2019.

    Hate the idea of a desk job? Want to do something amazing in science? We're hiring technicians in cell culture, molecular biology and expression, and sequencing!

    Poništi
  16. 25. ožu 2019.

    AbCellera's Dr Kevin Heyries and Caitlin Webster will be speaking at Biotech Expo tomorrow. Find out about interesting careers in science and what it's like to start a biotech company in

    Poništi
  17. 20. ožu 2019.
    Poništi
  18. 20. ožu 2019.

    AbCellera is going to be at . Find out how we're building complex data visualization and analysis tools, leveraging rich antibody datasets and machine learning. Don't know what an is? Ask us!

    Poništi
  19. 14. ožu 2019.

    The collaborations funded under the present agreement will benefit from AbCellera’s new technology capabilities for deep profiling of antibody responses.

    Poništi
  20. 14. ožu 2019.

    AbCellera today announced a two-year agreement with the to help accelerate global health research.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·